DDrare: Database of Drug Development for Rare Diseases

Searched query = "Angelman syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aknemin; Aknemin 50; Betaine; Carbidopa; Creatine; GABOXADOL MONOHYDRATE; GTX-102; Gaboxadol; Gaboxadol monohydrate 0.5 mg; Gaboxadol monohydrate 0.5 mg (intended commercial formulation); Gaboxadol monohydrate 0.5 mg capsule; Gaboxadol monohydrate 2 mg; Gaboxadol monohydrate 2 mg (intended commercial formulation); Gaboxadol monohydrate 2 mg capsule; Gaboxadol monohydrate 5 mg; Gaboxadol monohydrate 5 mg (intended commercial formulation); Levodopa; Levodopa/Carbidopa (4:1); MINOCYCLINE; MINOCYCLINE HYDROCHLORIDE; Metafolin; Minocycline; Nutritional Formulation Containing Exogenous Ketones; OV101; OV101 Regimen 1; OV101 regimen 2; RO7248824; RO7248824/F02-01; RO7248824/F03-01 (Diluent for RO7248824/F02-01; Vitamin B12

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00829439 (ClinicalTrials.gov)	January 2009	26/1/2009	Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome	A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome	Angelman Syndrome	Drug: Levodopa /Carbidopa (4:1)	Boston Children’s Hospital	NULL	Completed	4 Years	12 Years	All	16	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00829439
(ClinicalTrials.gov)

January 2009

26/1/2009

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome

Angelman Syndrome

Drug: Levodopa /Carbidopa (4:1)

Boston Children’s Hospital

NULL

Completed

4 Years

12 Years

All

Phase 1

United States